IFN-γ and Fas/FasL pathways cooperate to induce medial cell loss and neointimal lesion formation in allograft vasculopathy

Transplant Immunology

Volumn 22, Issue 3-4, 2010, Pages 157-164

  Hart Matyas, Michael ^a   Nejat, Sara ^a   Jordan, Julie L ^a   Hirsch, Gregory M ^a   Lee, Timothy D G ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Allograft arteriosclerosis; Allograft vasculopathy; Chronic rejection; Late graft rejection; Neointimal lesion; Transplantation

Indexed keywords

CYCLOSPORIN A; FAS LIGAND; GAMMA INTERFERON; GRANZYME; MESSENGER RNA; PERFORIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CD8+ T LYMPHOCYTE; CELL LOSS; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; HEART MUSCLE CELL; HOUSEKEEPING GENE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANTIGENS, CD95; AORTA; CALCINEURIN; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; LYMPHOCYTE COOPERATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PHOSPHOPROTEINS; TUNICA INTIMA; TUNICA MEDIA;

EID: 77951635592     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2009.10.004     Document Type: Article

References (64)

1. Hosenpud J.D., Bennett L.E., Keck B.M., Boucek M.M., Novick R.J. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant 2001, 20:805-815.
2. Hertz M.I., Taylor D.O., Trulock E.P., Boucek M.M., Mohacsi P.J., Edwards L.B., et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Official Report-2002. J Heart Lung Transplant 2002, 21:950-970.
3. Ramzy D., Rao V., Brahm J., Miriuka S., Delgado D., Ross H.J. Cardiac allograft vasculopathy: a review. Can J Surg 2005, 48:319-327.
4. Mitchell R.N., Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 2007, 100:967-978.
5. Eisen H.J., Tuzcu E.M., Dorent R., Kobashigawa J., Mancini D. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847-858.
6. Keogh A., Richardson M., Ruygrok P., Spratt P., Galbraith A., O'Driscoll G., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2years: a randomized clinical trial. Circulation 2004, 110:2694-2700.
7. Vigano M., Tuzcu M., Benza R., Boissonnat P., Haverich A., Hill J., et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007, 26:584-592.
8. Delgado J.F., Manito N., Segovia J., Almenar L., Arizon J.M., Camprecios M., et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando ) 2009, 23:69-79.
9. Raichlin E., Kushwaha S.S. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr Opin Organ Transplant 2008, 13:543-550.
10. Kaczmarek I., Ertl B., Schmauss D., Sadoni S., Knez A., Daebritz S., et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006, 25:550-556.
11. Libby P., Pober J.S. Chronic rejection. Immunity 2001, 14:387-397.
12. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
13. Hernandez J.M., de Prada J.A., Burgos V., Sainz L.F., Valls M.F., Vilchez F.G., et al. Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20years after heart transplantation. J Heart Lung Transplant 2009, 28:156-162.
14. Patten R.D. Virtual histology intravascular ultrasound assessing the risk of cardiac allograft vasculopathy. J Am Coll Cardiol 2009, 53:1287-1288.
15. Osto E., Tona F., Angelini A., Montisci R., Ruscazio M., Vinci A., et al. Determinants of coronary flow reserve in heart transplantation: a study performed with contrast-enhanced echocardiography. J Heart Lung Transplant 2009, 28:453-460.
16. Johnson P., Carpenter M., Hirsch G., Lee T. Recipient cells form the intimal proliferative lesion in the rat aortic model of allograft arteriosclerosis. Am J Transplant 2002, 2:207-214.
17. Shimizu K., Sugiyama S., Aikawa M., Fukumoto Y., Rabkin E., Libby P., et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001, 7:738-741.
18. Saiura A., Sata M., Hirata Y., Nagai R., Makuuchi M. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001, 7:382-383.
19. Li J., Han X., Jiang J., Zhong R., Williams G.M., Pickering J.G., et al. Vascular smooth muscle cells of recipient origin mediate intimal expansion after aortic allotransplantation in mice. Am J Pathol 2001, 158:1943-1947.
20. Hillebrands J.L., Klatter F.A., van den Hurk B.M., Popa E.R., Nieuwenhuis P., Rozing J. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001, 107:1411-1422.
21. Hillebrands J.L., Klatter F.A., Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:380-387.
22. Hruban R.H., Long P.P., Perlman E.J., Hutchins G.M., Baumgartner W.A., Baughman K.L., et al. Fluorescence in situ hybridization for the Y-chromosome can be used to detect cells of recipient origin in allografted hearts following cardiac transplantation. Am J Pathol 1993, 142:975-980.
23. Grimm P.C., Nickerson P., Jeffery J., Savani R.C., Gough J., McKenna R.M., et al. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 2001, 345:93-97.
24. Quaini F., Urbanek K., Beltrami A.P., Finato N., Beltrami C.A., Nadal-Ginard B., et al. Chimerism of the transplanted heart. N Engl J Med 2002, 346:5-15.
25. Atkinson C., Horsley J., Rhind-Tutt S., Charman S., Phillpotts C.J., Wallwork J., et al. Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor origin. J Heart Lung Transplant 2004, 23:427-435.
26. Zaki AM, Hirsch GM, Lee TD Contribution of pre-existing vascular disease to allograft vasculopathy in a murine model. Transpl Immunol 2009, [Electronic publication ahead of print].
27. Chow L.H., Huh S., Jiang J., Zhong R., Pickering J.G. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation 1996, 94:3079-3082.
28. Shi C., Lee W.S., He Q., Zhang D., Fletcher D.L., Newell J.B., et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996, 93:4051-4056.
29. Russell P.S., Chase C.M., Winn H.J., Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994, 152:5135-5141.
30. Gareau A., Hirsch G.M., Lee T.D., Nashan B. Contribution of B cells and antibody to cardiac allograft vasculopathy. Transplantation 2009, 88:470-477.
31. Skaro A.I., Liwski R.S., O'Neill J., Vessie E.L., Zhou J., Hirsch G.M., et al. Impairment of recipient cytolytic activity attenuates allograft vasculopathy. Transpl Immunol 2005, 14:27-35.
32. Skaro A.I., Liwski R.S., Zhou J., Vessie E.L., Lee T.D., Hirsch G.M. 8+ T cells mediate aortic allograft vasculopathy by direct killing and an interferon-gamma-dependent indirect pathway. Cardiovasc Res 2005, 65:283-291.
33. Vessie E.L., Hirsch G.M., Lee T.D. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol 2005, 15:35-44.
34. Koulack J., McAlister V.C., Giacomantonio C.A., Bitter-Suermann H., MacDonald A.S., Lee T.D.G. Development of a mouse aortic transplant model of chronic rejection. Microsurgery 1995, 16:110-113.
35. Hirsch G.M., Kearsey J., Burt T., Karnovsky M.J., Lee T. Medial smooth muscle cell loss in arterial allografts occurs by cytolytic cell induced apoptosis. Eur J Cardiothorac Surg 1998, 14:89-97.
36. Untergasser A., Nijveen H., Rao X., Bisseling T., Geurts R., Leunissen J.A.M. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 2007, 35:W71-W74.
37. Hellemans J., Mortier G., De Paepe A., Speleman F., Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007, 8:R19.
38. Nejat S., Zaki A., Hirsch G.M., Lee T.D. CD8(+) T cells mediate aortic allograft vasculopathy under conditions of calcineurin immunosuppression: role of IFN-gamma and CTL mediators. Transpl Immunol 2008, 19:103-111.
39. Rosner D., Stoneman V., Littlewood T., McCarthy N., Figg N., Wang Y., et al. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a. Am J Pathol 2006, 168:2054-2063.
40. Choy J.C., Cruz R.P., Kerjner A., Geisbrecht J., Sawchuk T., Fraser S.A., et al. Granzyme B induces endothelial cell apoptosis and contributes to the development of transplant vascular disease. Am J Transplant 2005, 5:494-499.
41. Rahmani M., Cruz R.P., Granville D.J., McManus B.M. Allograft vasculopathy versus atherosclerosis. Circ Res 2006, 99:801-815.
42. Krupnick A.S., Kreisel D., Popma S.H., Balsara K.R., Szeto W.Y., Krasinskas A.M., et al. Mechanism of T cell-mediated endothelial apoptosis. Transplantation 2002, 74:871-876.
43. Reidy M.A. Factors controlling smooth-muscle cell proliferation. Arch Pathol Lab Med 1992, 116:1276-1280.
44. Currie M., Zaki A.M., Nejat S., Hirsch G.M., Lee T.D. Immunologic targets in the etiology of allograft vasculopathy: endothelium versus media. Transpl Immunol 2008, 19:120-126.
45. Vessie E.L., Hirsch G.M., Lee T.D. Aortic allograft vasculopathy is mediated by CD8(+) T cells in Cyclosporin A immunosuppressed mice. Transpl Immunol 2005, 15:35-44.
46. Akyurek L.M., Johnsson C., Lange D., Georgii-Hemming P., Larsson E., Fellstrom B.C., et al. Tolerance induction ameliorates allograft vasculopathy in rat aortic transplants. Influence of Fas-mediated apoptosis. J Clin Invest 1998, 101:2889-2899.
47. Xu B., Sakkas L.I., Slachta C.A., Goldman B.I., Jeevanandam V., Oleszak E.L., et al. Apoptosis in chronic rejection of human cardiac allografts. Transplantation 2001, 71:1137-1146.
48. Nejat S., Zaki A., Hirsch G.M., Lee T.D. CD8(+) T cells mediate aortic allograft vasculopathy under conditions of calcineurin immunosuppression: role of IFN-gamma and CTL mediators. Transpl Immunol 2008, 19:103-111.
49. Russell M.E., Raisanen-Sokolowski A., Mottram P., Glysing-Jensen T. Knockout models of chronic cardiac rejection and graft arteriosclerosis: intimal thickening develops independent of Th1 and Th2 cytokines. Transplant Proc 1997, 29:2531-2532.
50. Russell M.E., Wallace A.F., Hancock W.W., Sayegh M.H., Adams D.H., Sibinga N.E., et al. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation 1995, 59:572-578.
51. Nagano H., Libby P., Taylor M.K., Hasegawa S., Stinn J.L., Becker G., et al. Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol 1998, 152:1187-1197.
52. Mazanet M.M., Neote K., Hughes C.C. Expression of IFN-inducible T cell alpha chemoattractant by human endothelial cells is cyclosporin A-resistant and promotes T cell adhesion: implications for cyclosporin A-resistant immune inflammation. J Immunol 2000, 164:5383-5388.
53. Raisky O., Spriewald B.M., Morrison K.J., Ensminger S., Mohieddine T., Obadia J.F., et al. CD8(+) T cells induce graft vascular occlusion in a CD40 knockout donor/recipient combination. J Heart Lung Transplant 2003, 22:177-183.
54. Zhao D.X., Hu Y., Miller G.G., Luster A.D., Mitchell R.N., Libby P. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 169:1556-1560.
55. Yi T., Cuchara L., Wang Y., Koh K.P., Ranjbaran H., Tellides G., et al. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma. Transplantation 2006, 81:559-566.
56. Tellides G., Tereb D.A., Kirkiles-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S., et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403:207-211.
57. Bai Y., Ahmad U., Wang Y., Li J.H., Choy J.C., Kim R.W., et al. Interferon-gamma induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J Biol Chem 2008, 283:6832-6842.
58. Dong C, Wilson JE, Winters GL, McManus BM Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Laboratory Investigation; J Tech Methods Pathol. 1996, 74:921-931.
59. Moldovan N.I., Qian Z., Chen Y., Dong C., Ying A., Hruban R.H., et al. Fas-mediated apoptosis in accelerated graft arteriosclerosis. Angiogenesis 1998, 2:245-254.
60. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997, 17:2200-2208.
61. Granville D.J., Chamberlain C.M. The role of Granzyme B in atheromatous diseases. Can J Physiol Pharmacol 2007, 85:89-95.
62. Boivin WA, Cooper DM, Hiebert PR, Granville DJ Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009, 89:1195-1220.
63. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-293.
64. Chan S.W., Hegyi L., Scott S., Cary N.R.B., Weissberg P.L., Bennett M.R. Sensitivity to Fas-mediated apoptosis is determined below receptor level in human vascular smooth muscle cells. Circ Res 2000, 86:1038-1046.